Nabriva Therapeutics Reports 2017 Financial Results and Recent Corporate Highlights

Nabriva Therapeutics (NASDAQ:NBRV), a clinical-stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced its financial results for the year ended December 31, 2017 and recent corporate highlights.

As quoted in the press release:

“We achieved a significant milestone in our clinical development program for lefamulin in 2017 with the announcement of positive topline data from our first global, IV-to-oral Phase 3 clinical trial in adult patients with moderate to severe CABP, known as LEAP 1,” said Dr. Colin Broom, chief executive officer of Nabriva Therapeutics.

Click here to read the full press release.